Literature DB >> 8219205

Analysis of p53 mutations in a large series of lymphoid hematologic malignancies of childhood.

M Wada1, C R Bartram, H Nakamura, M Hachiya, D L Chen, J Borenstein, C W Miller, L Ludwig, T E Hansen-Hagge, W D Ludwig.   

Abstract

p53 mutations are found in a wide variety of cancers, including hematologic malignancies. These alterations apparently contribute to development of the malignant phenotype. We analyzed a large series of lymphoid (330 cases) and a smaller series of myeloid (29 cases) malignancies of childhood for p53 mutations by single-strand conformational polymorphism (SSCP) following polymerase chain reaction. Samples with abnormal SSCP were reamplified and analyzed by direct sequencing method. p53 mutations were detected within the known mutational hotspots (exons 5 to 8) in 8 of 330 lymphoid malignancies, and in none of 29 myeloid malignancies, showing that the frequency of p53 mutations in childhood lymphoid malignancies was very low (8 of 330 cases [2%]). Four of these patients had very aggressive, fatal acute lymphocytic leukemia (ALL). None of 13 infants and none of 48 patients with T-lineage leukemia had detectable p53 mutations in their ALL cells. Exceptionally, p53 mutations were comparatively frequent in a small sample of B-cell non-Hodgkin's lymphomas (2 of 8 cases). Mutations were detected in samples from two patients with ALL at relapse; these were not detected in samples at initial diagnosis from the same patients, suggesting that p53 mutations may be associated with progression to a more malignant phenotype. Seven of eight alterations of p53 were missense mutations, and seven of eight samples may be heterozygous for the mutant p53, indicating that p53 protein may act in a dominant negative fashion.

Entities:  

Mesh:

Year:  1993        PMID: 8219205

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  34 in total

1.  Analysis of the frequency of microsatellite instability and p53 gene mutation in splenic marginal zone and MALT lymphomas.

Authors:  M Sol Mateo; M Mollejo; R Villuendas; P Algara; M Sánchez-Beato; B Martinez-Delgado; P Martínez; M A Piris
Journal:  Mol Pathol       Date:  1998-10

2.  NOTCH1 mutation, TP53 alteration and myeloid antigen expression predict outcome heterogeneity in children with first relapse of T-cell acute lymphoblastic leukemia.

Authors:  Jana Hof; Corinne Kox; Stefanie Groeneveld-Krentz; Obul R Bandapalli; Leonid Karawajew; Katharina Schedel; Joachim B Kunz; Cornelia Eckert; Wolf-Dieter Ludwig; Richard Ratei; Peter Rhein; Günter Henze; Martina U Muckenthaler; Andreas E Kulozik; Arend von Stackelberg; Renate Kirschner-Schwabe
Journal:  Haematologica       Date:  2017-03-30       Impact factor: 9.941

3.  TP53 mutations are frequent in adult acute lymphoblastic leukemia cases negative for recurrent fusion genes and correlate with poor response to induction therapy.

Authors:  Sabina Chiaretti; Fulvia Brugnoletti; Simona Tavolaro; Silvia Bonina; Francesca Paoloni; Marilisa Marinelli; Nancy Patten; Massimiliano Bonifacio; Maria Grazia Kropp; Simona Sica; Anna Guarini; Robin Foà
Journal:  Haematologica       Date:  2013-02-12       Impact factor: 9.941

4.  Indole-3-carbinol suppresses NF-κB activity and stimulates the p53 pathway in pre-B acute lymphoblastic leukemia cells.

Authors:  Majid Safa; Behnaz Tavasoli; Rima Manafi; Fatemeh Kiani; Meysam Kashiri; Saber Ebrahimi; Ahmad Kazemi
Journal:  Tumour Biol       Date:  2015-01-15

Review 5.  A review of new agents evaluated against pediatric acute lymphoblastic leukemia by the Pediatric Preclinical Testing Program.

Authors:  L Jones; H Carol; K Evans; J Richmond; P J Houghton; M A Smith; R B Lock
Journal:  Leukemia       Date:  2016-07-15       Impact factor: 11.528

6.  Initial Testing (Stage 1) of MK-8242-A Novel MDM2 Inhibitor-by the Pediatric Preclinical Testing Program.

Authors:  Min H Kang; C Patrick Reynolds; E Anders Kolb; Richard Gorlick; Hernan Carol; Richard Lock; Stephen T Keir; John M Maris; Jianwrong Wu; Dmitry Lyalin; Raushan T Kurmasheva; Peter J Houghton; Malcolm A Smith
Journal:  Pediatr Blood Cancer       Date:  2016-05-30       Impact factor: 3.167

7.  Human chromosomal translocations at CpG sites and a theoretical basis for their lineage and stage specificity.

Authors:  Albert G Tsai; Haihui Lu; Sathees C Raghavan; Markus Muschen; Chih-Lin Hsieh; Michael R Lieber
Journal:  Cell       Date:  2008-12-12       Impact factor: 41.582

Review 8.  Identifying novel therapeutic agents using xenograft models of pediatric cancer.

Authors:  Raushan T Kurmasheva; Peter J Houghton
Journal:  Cancer Chemother Pharmacol       Date:  2016-05-18       Impact factor: 3.333

9.  Loss of nuclear expression of the p33(ING1b) inhibitor of growth protein in childhood acute lymphoblastic leukaemia.

Authors:  G S Nouman; J J Anderson; K M Wood; J Lunec; A G Hall; M M Reid; B Angus
Journal:  J Clin Pathol       Date:  2002-08       Impact factor: 3.411

Review 10.  Apoptosis, cancer and the p53 tumour suppressor gene.

Authors:  J M Lee; A Bernstein
Journal:  Cancer Metastasis Rev       Date:  1995-06       Impact factor: 9.264

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.